コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
4 c signaling pathways in fibroblasts from the palmar and nonpalmar dermis of Dupuytren's patients and
5 ling arthritic changes, marked osteoporosis, palmar and plantar subcutaneous nodules and distinctive
6 rome include multiple basal cell carcinomas, palmar and/or plantar pits, odontogenic keratocysts, ske
12 romoted differentiation into specifically of palmar dermal fibroblasts from Dupuytren's patients in t
13 ith the peak systolic velocity of the second palmar digital artery (Pearson coefficient: 0.621; p < 0
14 CR) analysis and immunohistochemistry of the palmar epidermis demonstrated significantly increased ex
15 ratum granulosum of both normal and affected palmar epidermis, indicating that the altered AQP5 prote
17 disabling fibroproliferative disorder of the palmar fascia, which leads to flexion contractures of th
23 mediate phenotype most readily identified by palmar hyperlinearity and in some cases fine-scale and/o
26 ong adduction of the thenar, hypothenar, and palmar interosseous muscles offer powerful rigidity to t
27 il thickening in PC-K6a and PC-K17; (3) more palmar keratoderma in PC-K16; (4) cysts primarily in PC-
29 pe of EPP which is characterized by seasonal palmar keratoderma, relatively low erythrocyte protoporp
33 nt but required early dose reductions due to palmar plantar erythrodysesthesia, and liver decompensat
35 , fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthesia (18 [6%]) in the sora
36 n with sorafenib than with axitinib included palmar-plantar erythrodysaesthesia (PPE; 37 [39%] of 96
37 ] vs 7 [2%]), fatigue (36 [11%] vs 24 [7%]), palmar-plantar erythrodysaesthesia syndrome (27 [8%] vs
38 hoea (103 [21%] of 488 patients) followed by palmar-plantar erythrodysaesthesia syndrome (87 [18%]),
39 fatigue in the axitinib arm, and diarrhoea, palmar-plantar erythrodysaesthesia, and alopecia in the
41 atigue (6% v 15%), hypertension (28% v 22%), palmar-plantar erythrodysesthesia (8% v 4%), and hematol
43 cause of adverse events related to the drug (palmar-plantar erythrodysesthesia [PPE], n = 3; asthenia
45 fatigue, hypertension, febrile neutropenia, palmar-plantar erythrodysesthesia syndrome, and stomatit
46 ncidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapat
48 mg twice per day; n = 1); grade 3 mucositis, palmar-plantar erythrodysesthesia, and hypokalemia (400
50 of whom had three dose-limiting toxicities: palmar-plantar erythrodysesthesia, cerebral ischaemia, a
51 associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and
52 5% of patients) were diarrhea, nausea, rash, palmar-plantar erythrodysesthesia, mucositis, vomiting,
53 as 1,657 mg/m2/d with limiting toxicities of palmar-plantar erythrodysesthesia, nausea, vomiting, ver
54 ction, elevated thyroid stimulating hormone, palmar-plantar erythrodysesthesia, weight loss, and head
56 on in a family with diffuse nonepidermolytic palmar-plantar keratoderma was shown to be the loss in o
63 , radioscapholunate, dorsal radiotriquetral, palmar scaphotriquetral, and dorsal scaphotriquetral lig
64 By simulating skin deformations across the palmar surface of the hand and tiling it with receptors
65 Injection of capsaicin into the plantar or palmar surface of the paws produced a depression of brad
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。